IBJNews

BrightPoint executive Howell stepping down

Back to TopCommentsE-mailPrintBookmark and Share

A longtime high-ranking executive for BrightPoint Inc. in Indianapolis will resign effective Jan. 18, three months after California-based Ingram Micro Inc. acquired the company.

J. Mark Howell, who became president of the company's North American region after BrightPoint merged into Santa Ana-based Ingram in October, resigned to “pursue personal interests,” Ingram said in a prepared statement.

He leaves after 18 years in upper management at BrightPoint, which provides logistics and distribution services to the mobile technology industry.

A golden parachute clause in Ingram’s $840 million acquisition agreement provided Howell with approximately $6.7 million as he and five other executives split $30.7 million in payouts.

Bashar Nejdawi will step into Howell’s position, the company said.

Nejdawi has most recently been the senior vice president of corporate strategic initiatives and partnerships for BrightPoint and Ingram Micro Mobility. He began working for the company in 2008 as president of the mobile enhancement business.

Howell’s departure comes as Ingram determines how BrightPoint, with its focus on logistics services for handheld mobile device companies, will fit into the operations of its new, much larger parent, which focuses on broader IT services.

Before the merger, BrightPoint had 4,000 employees worldwide, with 1,100 people in central Indiana.

Ingram has remained silent on possible layoffs. But cost-cutting will likely happen in some capacity as the IT service provider eyes $55 million in "cost synergies."

ADVERTISEMENT

  • $$$
    Another Brightpoint exec leaves with millions in his pocket. Who's next?
  • Best of Luck
    Congrats, Mr. Howell, on a great ride. Your value to our community cannot be understated. You are a great leader and servant. Best wishes for your next endeavor.

    Post a comment to this story

    COMMENTS POLICY
    We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
     
    You are legally responsible for what you post and your anonymity is not guaranteed.
     
    Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
     
    No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
     
    We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
     

    Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

    Sponsored by
    ADVERTISEMENT

    facebook - twitter on Facebook & Twitter

    Follow on TwitterFollow IBJ on Facebook:
    Follow on TwitterFollow IBJ's Tweets on these topics:
     
    Subscribe to IBJ
    1. So, Pence wants the federal government to ignore the 2008 law that allows children from these countries to argue for asylum in front of a judge. How did this guy become governor? And how is that we'll soon be subjected to repeatedly seeing him on TV being taken seriously as a presidential candidate? Am I in Bizzaro-U.S.A.?

    2. "And the most rigorous studies of one-year preschool programs have shown short-term benefits that fade out in a few years or no benefits at all." So we are going down a path that seems to have proven not to work very well. Right intention, wrong approach?

    3. Well for Dunkin Donuts it might say that even a highly popular outlet can't make a poorly sited location work. That little strip has seen near constant churn for years.

    4. Years ago, the Pharmaceutical and Medical Device companies shifted their research investment away from Medical Institutions to focus more on private research centers, primarily because of medical institution inefficiencies in initiating clinical studies and their inability/commitment to enroll the needed number of patients in these studies. The protracted timelines of the medical institutions were prompting significant delays in the availability of new drug and medical device entities for patients and relatedly, higher R and D expenditures to the commercial industry because of these delays. While the above stated IU Health "ratio is about $2.50 in federal funding for every $1 in industry funding", the available funding is REVERSED as commercial R and D (primarily Phase I-IV clinical work)runs $2.50 to $1 for available federal funding ($76.8B to $30.9B in 2011). The above article significatly understated the available R and D funding from industry......see the Pharma and Medical Device industry websites. Clearly, if medical institutions like IU Health wish to attract more commercial studies, they will need to become more competitive with private clinical sites in their ability to be more efficient and in their commitment to meet study enrollment goals on time. Lastly, to the reference to the above Washington Post article headlined “As drug industry’s influence over research grows, so does the potential for bias", lacks some credibility as both FDA and Institutional Institutional Review Boards must approve the high proportion of these studies before studies are started. This means that both study safety and science must be approved by both entities.

    5. ChIeF and all the other critics – better is better no matter what. Get over it; they are doing better despite you ?

    ADVERTISEMENT